These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16079871)

  • 1. TZDs and diabetes: testing the waters.
    Semenkovich CF
    Nat Med; 2005 Aug; 11(8):822-4. PubMed ID: 16079871
    [No Abstract]   [Full Text] [Related]  

  • 2. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.
    Guan Y; Hao C; Cha DR; Rao R; Lu W; Kohan DE; Magnuson MA; Redha R; Zhang Y; Breyer MD
    Nat Med; 2005 Aug; 11(8):861-6. PubMed ID: 16007095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
    Ahmed I; Furlong K; Flood J; Treat VP; Goldstein BJ
    Am J Ther; 2007; 14(1):49-62. PubMed ID: 17303976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes drugs offered fresh start.
    Ledford H
    Nature; 2010 Jul; 466(7305):420-1. PubMed ID: 20651662
    [No Abstract]   [Full Text] [Related]  

  • 6. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
    Lehmann DF; Lohray BB
    J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
    [No Abstract]   [Full Text] [Related]  

  • 7. Releasing the pressure.
    Davenport RJ
    Sci Aging Knowledge Environ; 2005 Jun; 2005(25):nf47. PubMed ID: 15975897
    [No Abstract]   [Full Text] [Related]  

  • 8. Thiazolidinediones in dermatology.
    Boyd AS
    Int J Dermatol; 2007 Jun; 46(6):557-63. PubMed ID: 17550551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ; Usher MG; Mortensen RM
    Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].
    Szymborska-Kajanek A; Strojek K
    Kardiol Pol; 2006 Mar; 64(3):322-5; discussion 325-6. PubMed ID: 16583340
    [No Abstract]   [Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
    Blaschke F; Caglayan E; Hsueh WA
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis.
    Decker M; Hofflich H; Elias AN
    Diabetes Obes Metab; 2008 Aug; 10(8):617-25. PubMed ID: 17645549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE; Hanna A
    Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPARgamma agonists, modulation of ion transporters, and fluid retention.
    Nofziger C; Blazer-Yost BL
    J Am Soc Nephrol; 2009 Dec; 20(12):2481-3. PubMed ID: 19820124
    [No Abstract]   [Full Text] [Related]  

  • 17. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
    Chetty VT; Sharma AM
    Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential.
    Yang J; Zhang D; Li J; Zhang X; Fan F; Guan Y
    Clin Sci (Lond); 2009 Jan; 116(1):17-26. PubMed ID: 19037881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPAR-gamma: therapeutic target for ischemic stroke.
    Culman J; Zhao Y; Gohlke P; Herdegen T
    Trends Pharmacol Sci; 2007 May; 28(5):244-9. PubMed ID: 17416424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.